Tolvaptan

(Jynarque®)

Jynarque®

Drug updated on 5/17/2024

Dosage FormTablet (oral; 15 mg, 30 mg, 45 mg, 60 mg and 90 mg)
Drug ClassSelective vasopressin V2-receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Tolvaptan (Jynarque) is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). It has proven effective in delaying the decline of estimated glomerular filtration rate and reducing the increase in total kidney volume, as well as minimizing complications like renal pain, urinary tract infections, hematuria, and hypertension.
  • The analysis stemmed from three systematic reviews/meta-analyses, which collectively involved a large number of patients across multiple trials for comprehensive evaluation.
  • In comparison with placebo treatments, Tolvaptan showed superior efficacy in preserving kidney function and inhibiting total kidney volume growth. However, it also exhibited a higher incidence of adverse events such as thirst, polyuria, and hepatic injury.
  • Compared to other ADPKD treatments, including tyrosine kinase inhibitors, mTOR inhibitors, and somatostatin analogs, while somatostatin analogs were more effective than both placebo and Tolvaptan at inhibiting TKV growth specifically; overall effectiveness still favored Tolvaptan due to its ability to better preserve general renal functions.
  • Safety concerns related to this drug include an increased risk for liver injury, along with symptoms like excessive thirst or urine production. These are significant when compared against placebos but have not been directly contrasted with side effects profiles from other ADPKD treatment options within the studies reviewed.
  • No specific subgroup considerations were mentioned within the analyzed studies regarding population types such as ethnic groups or age subgroups beyond diagnosis status itself being considered during the analysis process. However, understanding how different patient demographics might respond differently remains a crucial aspect toward personalized treatment planning strategies involving scenarios where Jynarque could be utilized.